Kymera reports Q4 2022 net loss $34.9M; cash $559.5M; Sanofi to start KT-474 Phase 2 in 2023

Kymera Therapeutics, Inc.

2022-FY EPS reported -$2.87 revenue$46,826,000

Net loss Q4 2022: $34.9M, full year $154.8M; cash and investments $559.5M as of Dec 31, 2022, runway into H2 2025.
Collaboration revenue Q4 $16.1M, full year $46.8M; R&D expenses $43.1M Q4, $164.2M full year.
Sanofi to initiate Phase 2 trial of KT-474 (IRAK4 degrader) in hidradenitis suppurativa and atopic dermatitis in 2023.
Phase 1 trials for KT-333 (STAT3) and KT-413 (IRAKIMiD) ongoing; clinical activity data expected in 2023.
KT-253 (MDM2) IND cleared; Phase 1 trial to start early 2023 in solid tumors and hematological malignancies.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Kymera Therapeutics, Inc. reported financial results for the quarter ended December 31, 2022.

Period: the quarter ended December 31, 2022
Result: reported results

Exact text from the filing

On February 23, 2023, Kymera Therapeutics, Inc. announced its financial results for the quarter ended December 31, 2022 and for the fiscal year ended December 31, 2022.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Kymera Therapeutics, Inc. reported financial results for the fiscal year ended December 31, 2022.

Period: the fiscal year ended December 31, 2022
Result: reported results

Exact text from the filing

On February 23, 2023, Kymera Therapeutics, Inc. announced its financial results for the quarter ended December 31, 2022 and for the fiscal year ended December 31, 2022.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Kymera Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-003930

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.